| Safety, Tolerability, Pharmacokinetics and Early Pharmacodynamics of Single Rising Oral Doses of BI 1021958 Tablets in Healthy Male Volunteers (NCT01541488) | Boehringer Ingelheim | 2012-02-01 |
| A Study to Determine the Effect of Tiotropium + Olodaterol Fixed Dose Combination on Exercise Endurance Time During Constant Work Rate Cycle Ergometry Test in COPD (NCT01525615) | Boehringer Ingelheim | 2012-02-01 |
| First in Man Trial of BI 113608 (NCT01540825) | Boehringer Ingelheim | 2012-02-01 |
| Pharmacokinetics of Fixed Dose Combination (FDC) Tablets of Linagliptin /Metformin (NCT01540487) | Boehringer Ingelheim | 2012-02-01 |
| This Trial Evaluates Safety, Pharmacokinetic Profile and Anti-viral Response of BI 207127 and BI 201335 for Patients With Chronic Hepatitis C (NCT01528735) | Boehringer Ingelheim | 2012-02-01 |
| LUX-Head&Neck 1: A Phase III Trial of Afatinib (BIBW2992) Versus Methotrexate for the Treatment of Recurrent and/or Metastatic (R/M) Head and Neck Squamous Cell Cancer After Platinum Based Chemotherapy (NCT01345682) | Boehringer Ingelheim | 2012-01-05 |
| Linagliptin and Metformin Versus Linagliptin in Newly Diagnosed, Untreated Type 2 Diabetes (NCT01512979) | Boehringer Ingelheim | 2012-01-01 |
| Single Rising Dose Study (Intravenous Infusion and Subcutaneous Injection) of BI 655064 in Healthy Male Volunteers (NCT01510782) | Boehringer Ingelheim | 2012-01-01 |
| Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Doses (NCT01505894) | Boehringer Ingelheim | 2012-01-01 |
| LUX-Lung 7: A Phase IIb Trial of Afatinib(BIBW2992) Versus Gefitinib for the Treatment of 1st Line EGFR Mutation Positive Adenocarcinoma of the Lung (NCT01466660) | Boehringer Ingelheim | 2011-12-13 |
| Post-Marketing Surveillance of Prazaxa® on the Long-term Use in Patients With Nonvalvular Atrial Fibrillation (NCT01491178) | Boehringer Ingelheim | 2011-12-12 |
| Follow on Study From RE-ALIGN (NCT01505881) | Boehringer Ingelheim | 2011-12-01 |
| Assessment of Exposure of BI 409306 in Cerebrospinal Fluid (CSF) Relative to Plasma as Well as to Evaluation of the Effect of Different Doses of BI 409306 on the cGMP (Cyclic Guanosine Monophosphate) Levels in CSF in Healthy Male Volunteers (NCT01493570) | Boehringer Ingelheim | 2011-12-01 |
| A Prospective, Open Label Study Evaluating Two Management Strategies on Gastrointestinal Symptoms in Patients Newly on Treatment With Pradaxa for the Prevention of Stroke and Systemic Embolism With Non-valvular Atrial Fibrillation (NCT01493557) | Boehringer Ingelheim | 2011-12-01 |
| Pharmacokinetics and Safety Study of BI 695501 in Healthy Subjects (NCT01505491) | Boehringer Ingelheim | 2011-12-01 |
| GLORIA-AF Registry Program - Second and Third Phases (NCT01468701) | Boehringer Ingelheim | 2011-11-07 |
| Observational Study of Adherence to LABA / LAMA in Chronic Obstructive Pulmonary Disease (COPD) (NCT01937390) | Boehringer Ingelheim | 2011-11-06 |
| Study on BI 54903 (Inhaled Corticosteroid) Administered Once Daily or Twice Daily Via Respimat Inhaler in Patients With Asthma Inadequately Controlled on Short Acting Beta-2 Agonist (SABA) Therapy Alone (NCT01458886) | Boehringer Ingelheim | 2011-11-01 |
| Linagliptin in Combination With Metformin in Treatment Naive Patients With Type 2 Diabetes Mellitus and Insufficient Glycaemic Control (NCT01438814) | Boehringer Ingelheim | 2011-11-01 |
| Assessment of Health-status of Patients With Chronic Obstructive Pulmonary Disease (COPD) on Maintenance Therapy With Spiriva HH Measured by COPD Assessment Test (CAT) Test (NCT01644734) | Boehringer Ingelheim | 2011-11-01 |
| Study on BI 54903 (Inhaled Corticosteroid) Administered Once Daily or Twice Daily Via Respimat Inhaler in Patients With Asthma Inadequately Controlled on Low Dose Inhaled Corticosteroids (NCT01458912) | Boehringer Ingelheim | 2011-11-01 |
| Tiotropium (18mcg) in Chronic Obstructive Pulmonary Disease (COPD) Patients With a Respiratory Infection (NCT01483625) | Boehringer Ingelheim | 2011-11-01 |
| Relative Bioavailability Study Between Two Formulations Containing Ambroxol Hydrochloride (NCT02572609) | Boehringer Ingelheim | 2011-11-01 |
| Single Rising Dose Study of BI 144807 Powder in Bottle in Healthy Male Volunteers (NCT01480648) | Boehringer Ingelheim | 2011-11-01 |
| LUX-Head&Neck 2: A Phase III Trial of Afatinib (BIBW 2992) Versus Placebo for the Treatment of Head and Neck Squamous Cell Cancer After Treatment With Chemo-radiotherapy (NCT01345669) | Boehringer Ingelheim | 2011-10-17 |
| Olodaterol Bridging Study in Asthma (NCT01428622) | Boehringer Ingelheim | 2011-10-01 |
| Dabigatran Etexilate in Patients With Mechanical Heart Valves (NCT01452347) | Boehringer Ingelheim | 2011-10-01 |
| Lux-Breast 3; Afatinib Alone or in Combination With Vinorelbine in Patients With Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer Suffering From Brain Metastases (NCT01441596) | Boehringer Ingelheim | 2011-10-01 |
| Investigation of the Effect of Food on the Bioavailability of a 25 mg Empagliflozin Tablet as Well as Assessment of Dose Proportionality Between 10 mg and 25 mg Empagliflozin Tablets Under Fasting Conditions. (NCT01451775) | Boehringer Ingelheim | 2011-10-01 |
| Impact of Ramadan on Achieving Joint National Committee (JNC) 7 Treatment Goals in CV Risk Patients (NCT01853839) | Boehringer Ingelheim | 2011-10-01 |
| Phase III Trial of BI 201335 (Faldaprevir) in Treatment Naive (TN) and Relapser Hepatitis C Virus (HCV)-Human Immunodeficiency Virus (HIV) Coinfected Patients (STARTverso 4) (NCT01399619) | Boehringer Ingelheim | 2011-09-01 |
| ADESPI: Adherence to Spiriva® in Patients With COPD (Chronic Obstructive Pulmonary Disease), Measured by Morisky-8 (MMAS-8) Scale, in Routine Medical Practice (NCT01388166) | Boehringer Ingelheim | 2011-09-01 |
| Tiotropium+Olodaterol Fixed Dose Combination (FDC) Versus Tiotropium and Olodaterol in Chronic Obstructive Pulmonary Disease (COPD) (NCT01431274) | Boehringer Ingelheim | 2011-09-01 |
| Tiotropium +Olodaterol Fixed Dose Combination (FDC) Versus Tiotropium and Olodaterol in Chronic Obstructive Pulmonary Disease (COPD) (NCT01431287) | Boehringer Ingelheim | 2011-09-01 |
| Safety and PK Study of BIBF 1120 in Japanese Patients With IPF: Follow up Study From 1199.31(NCT01136174) (NCT01417156) | Boehringer Ingelheim | 2011-09-01 |
| To Assess the Bioequivalence of Brotizolam Tablets 250 Mcg vs. Lendormin Tablets 250 Mcg Administered to Healthy Adult Volunteers (NCT01361022) | Boehringer Ingelheim | 2011-08-01 |
| Investigation of Ritonavir Effects on Afatinib Exposure in Healthy Subjects (NCT01426958) | Boehringer Ingelheim | 2011-08-01 |
| A Study to Evaluate Efficacy and Safety of Tiotropium in Children 6 to 11 Years Old With Moderate Asthma (NCT01383499) | Boehringer Ingelheim | 2011-08-01 |
| BI 836826 Dose Escalation in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma (NHL) (NCT01403948) | Boehringer Ingelheim | 2011-08-01 |
| Relative Bioavailability of Bromhexine Given as Granules and Syrup in Healthy Volunteers (Clinical Phase I Study) (NCT01423721) | Boehringer Ingelheim | 2011-08-01 |
| Efficacy and Safety of Empagliflozin (BI 10773) / Linagliptin (BI 1356) Fixed Dose Combination in Treatment naïve and Metformin Treated Type 2 Diabetes Patients (NCT01422876) | Boehringer Ingelheim | 2011-08-01 |
| Afatinib (BIBW2992) in HER2 (Human Epidermal Growth Factor Receptor 2)-Overexpressing Inflammatory Breast Cancer (NCT01325428) | Boehringer Ingelheim | 2011-08-01 |
| Dose Finding Study on BI54903 (Inhaled Corticosteroid) Administered Twice Daily Via Respimat® Inhaler in Asthmatic Patients Inadequately Controlled on Short-acting-beta-agonist (SABA) Therapy (NCT01397162) | Boehringer Ingelheim | 2011-07-21 |
| Phase I Trial of BI 836845 for Various Solid Cancer (NCT01403974) | Boehringer Ingelheim | 2011-07-19 |
| A Study of BI 853520 in Patients With Various Types of Advanced or Metastatic Cancer (NCT01335269) | Boehringer Ingelheim | 2011-07-01 |
| Drug Interaction Study With Rifampicin and Afatinib (NCT01396265) | Boehringer Ingelheim | 2011-07-01 |
| A Rollover Study of BI 201335 in Combination With Pegylated Interferon-alpha and Ribavirin in Treatment-experienced Genotype 1 Hepatitis C Infected Patients (NCT01330316) | Boehringer Ingelheim | 2011-07-01 |
| Study on BI 54903 (Inhaled Corticosteroid) Administered Twice Daily Via Respimat Inhaler in Patients With Asthma Inadequately Controlled on Medium Dose Inhaled Corticosteroid (ICS). (NCT01396278) | Boehringer Ingelheim | 2011-07-01 |
| Study on BI 54903 (Inhaled Corticosteroid) Administered Twice Daily Via Respimat Inhaler in Patients With Asthma Inadequately Controlled on Low Dose Inhaled Corticosteroid (ICS) (NCT01397201) | Boehringer Ingelheim | 2011-07-01 |
| Comparison of the Bioavailability of Metformin Between Medium Dose Linagliptin/Metformin Tablets and Medium Dose Glucophage Tablet Given With Linagliptin Tablet (NCT01383356) | Boehringer Ingelheim | 2011-06-01 |
| 12 Week Efficacy and Safety Study of Empagliflozin (BI 10773) in Hypertensive Patients With Type 2 Diabetes Mellitus (NCT01370005) | Boehringer Ingelheim | 2011-06-01 |
| Efficacy and Safety of BI 201335 (Faldaprevir) in Combination With Pegylated Interferon-alpha and Ribavirin in Treatment-Experienced Genotype 1 Hepatitis C Infected Patients (STARTverso 3) (NCT01358864) | Boehringer Ingelheim | 2011-06-01 |
| Evaluation of the Effect of Multiple Dosing With BI 201335 on CYP2B6 Metabolism and Effect of Multiple Dosing With Efavirenz on the Steady-state Pharmacokinetics of BI 201335 and on CYP3A4/5 Metabolism in Healthy Volunteers (NCT01371006) | Boehringer Ingelheim | 2011-06-01 |
| Safety and Efficacy of Empagliflozin (BI 10773) in Type 1 Diabetes Mellitus Patients With or Without Renal Hyperfiltration (NCT01392560) | Boehringer Ingelheim | 2011-06-01 |
| Effect of Multiple Dosing With BI 201335 on the Pharmacokinetics of Darunavir Co-administered With Ritonavir in Healthy Male and Female Volunteers (NCT01374802) | Boehringer Ingelheim | 2011-06-01 |
| Phase I Study of AbGn-168H in Healthy Male Volunteers (NCT01378364) | Boehringer Ingelheim | 2011-06-01 |
| LUX-Breast 2; Afatinib in HER2 (Human Epidermal Growth Factor Receptor)-Treatment Failures (NCT01271725) | Boehringer Ingelheim | 2011-05-24 |
| GLORIA-AF Registry Program (Phase I) (NCT01428765) | Boehringer Ingelheim | 2011-05-01 |
| Single Rising Dose Study of BI 207127 NA in Healthy Male Asian Volunteers and Single Dose Study of BI 207127 NA in Healthy Male Caucasian Volunteers (NCT01347086) | Boehringer Ingelheim | 2011-05-01 |
| Safety and Efficacy of Daily Use of Micamlo® Combination Tablets AP in Patients With Hypertension (NCT01353274) | Boehringer Ingelheim | 2011-05-01 |
| Empagliflozin (BI 10773) Comprehensive add-on Study in Japanese Subjects With Type 2 Diabetes Mellitus (NCT01368081) | Boehringer Ingelheim | 2011-05-01 |
| Safety and Efficacy of BIBF 1120 at High Dose in Idiopathic Pulmonary Fibrosis Patients II (NCT01335477) | Boehringer Ingelheim | 2011-05-01 |
| Ambroxol Spray Sore Throat Study (NCT01361802) | Boehringer Ingelheim | 2011-05-01 |
| a PMS on Safety Profile of Pramipexole in Chinese Parkinson Disease Patients (NCT01361009) | Boehringer Ingelheim | 2011-05-01 |
| Safety, Tolerability and Pharmacokinetics of Single Rising Oral Doses of BI 137882 in Healthy Male Volunteers (NCT01348165) | Boehringer Ingelheim | 2011-05-01 |
| BI 6727 (Volasertib) Monotherapy Phase I Trial in Japanese Patients With Advanced Solid Tumours (NCT01348347) | Boehringer Ingelheim | 2011-04-25 |
| Monotherapy Dose Finding With BI 847325 in Solid Tumours (NCT01324830) | Boehringer Ingelheim | 2011-04-15 |
| A Phase I/II Study of Continuous Oral Treatment With BIBF 1120 Added to Standard Gemcitabine/Cisplatin Therapy in First Line NSCLC Patients With Squamous Cell Histology. (NCT01346540) | Boehringer Ingelheim | 2011-04-14 |
| Trial to Determine MTD of BI 836845 Administered Intravenously Once Every Three Weeks in Patients With Advanced Solid Tumours and Later a Weekly Dosing Schedule in Selected Tumour Types (NCT01317420) | Boehringer Ingelheim | 2011-04-13 |
| Drug-drug Interaction of Empagliflozin (BI 10773) and Microgynon (NCT01328184) | Boehringer Ingelheim | 2011-04-01 |
| Bioequivalence Study of Telmisartan Between Telmisartan 80 mg/Amlodipine 5 mg FDC Tablet and Telmisartan 80 mg Tab and Amlodipine 5 mg Tab Concomitant Use (NCT01344629) | Boehringer Ingelheim | 2011-04-01 |
| Efficacy and Safety of BI 201335 (Faldaprevir) in Combination With Pegylated Interferon-alpha and Ribavirin in Treatment-naïve Genotype 1 Hepatitis C Infected Patients (STARTverso 2) (NCT01297270) | Boehringer Ingelheim | 2011-04-01 |
| Finding a Safe and Effective Dose of Linagliptin in Pediatric Patients With Type 2 Diabetes (NCT01342484) | Boehringer Ingelheim | 2011-04-01 |
| Safety and Efficacy of BIBF 1120 at High Dose in Idiopathic Pulmonary Fibrosis Patients (NCT01335464) | Boehringer Ingelheim | 2011-04-01 |
| Efficacy and Safety of BI 201335 (Faldaprevir) in Combination With Pegylated Interferon-alpha and Ribavirin in Treatment-naïve Genotype 1 Hepatitis C Infected Patients (STARTverso 1) (NCT01343888) | Boehringer Ingelheim | 2011-04-01 |
| Dose Escalation Study of BIBF 1120 in Combination With Carboplatin and PLD in Relapsed Ovarian Cancer (OC) (NCT01329549) | Boehringer Ingelheim | 2011-04-01 |
| Single Rising Dose Study to Assess Safety, Tolerability and Pharmacokinetics of BI 661051. (NCT01343719) | Boehringer Ingelheim | 2011-04-01 |
| Evaluation of Tiotropium 2.5 and 5 µg Once Daily Delivered Via the Respimat Inhaler Compared to Placebo in Patient With Moderate to Severe Persistent Asthma (NCT01340209) | Boehringer Ingelheim | 2011-04-01 |
| Drug Drug Interaction of BI 201335 and Tenofovir (NCT01340196) | Boehringer Ingelheim | 2011-04-01 |
| Safety Tolerability and Pharmacokinetic of BI 409306 (NCT01343706) | Boehringer Ingelheim | 2011-04-01 |
| BIBF 1120 + Carboplatin/Pegylated Liposomal Doxorubicin (PLD) in Patients With Advanced Ovarian Cancer, Fallopian Tube Carcinoma or Primary Peritoneal Cancer (NCT01314105) | Boehringer Ingelheim | 2011-03-15 |
| Drug-drug Interaction Study of Aggrenox and Omeprazole in Normal Volunteers (NCT01303445) | Boehringer Ingelheim | 2011-03-01 |
| Pharmacokinetics of the Fixed Dose Combination of Tiotropium Plus BI 54903 Versus the Combination of the Monoproducts of Tiotropium and BI 54903 in Healthy Volunteers (NCT01309139) | Boehringer Ingelheim | 2011-03-01 |
| Twynsta Study With Lifestyle Modifications in Korean Patients With Hypertension (NCT01316419) | Boehringer Ingelheim | 2011-03-01 |
| Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Empagliflozin in Chinese Female and Male Patients With Type 2 Diabetes Mellitus (NCT01316341) | Boehringer Ingelheim | 2011-03-01 |
| SMS Reminder to Assess Adherence (NCT01308476) | Boehringer Ingelheim | 2011-03-01 |
| Efficacy and Safety of 2 Doses of Tiotropium Via Respimat in Adult Patients With Mild Persistent Asthma (NCT01316380) | Boehringer Ingelheim | 2011-03-01 |
| A Study to Compare the Efficacy and Safety of Different Dosings of Olodaterol Administered With the Respimat® Inhaler in Patients With Moderate to Severe Asthma (NCT01311661) | Boehringer Ingelheim | 2011-03-01 |
| BI836826 Dose Escalation in Relapsed Chronic Lymphocytic Leukaemia (CLL) (NCT01296932) | Boehringer Ingelheim | 2011-02-11 |
| Relative Bioavailability of Single Dose Empagliflozin (BI 10773) When Co-administered With Multiple Doses of 600 mg Gemfibrozil Compared to Single Dose Treatment With Empagliflozin (BI 10773) When Given Alone in Healthy Volunteers (NCT01301742) | Boehringer Ingelheim | 2011-02-01 |
| Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Oral Doses of BI 135585 XX in Patients With Type 2 Diabetes (NCT01282970) | Boehringer Ingelheim | 2011-02-01 |
| Safety and Efficacy of Empagliflozin (BI 10773) and Sitagliptin Versus Placebo Over 76 Weeks in Patients With Type 2 Diabetes (NCT01289990) | Boehringer Ingelheim | 2011-02-01 |
| The Use of Angiotensin Receptor Blockers and the Risk of Cancer (NCT02215733) | Boehringer Ingelheim | 2011-02-01 |
| Drug-drug Interaction of Empagliflozin (BI 10773) and Simvastatin (NCT01304329) | Boehringer Ingelheim | 2011-02-01 |
| Drug Interaction Study With Dabigatran Etexilate and Dronedarone in Healthy Subjects (NCT01306162) | Boehringer Ingelheim | 2011-02-01 |
| Influence of Mild and Moderate Hepatic Impairment on the Pharmacokinetics, Safety and Tolerability of Various Doses of Afatinib (NCT01298063) | Boehringer Ingelheim | 2011-02-01 |
| Single Rising Dose Study of BI 135585 XX in Health Asian Male Volunteers. (NCT01291732) | Boehringer Ingelheim | 2011-02-01 |
| Safety and Efficacy of BI 10773 as add-on to Insulin Regimen in Patients With Type 2 Diabetes Mellitus (NCT01306214) | Boehringer Ingelheim | 2011-02-01 |
| Drug Interaction Study of Digoxin and BI 10773 (NCT01306175) | Boehringer Ingelheim | 2011-02-01 |
| Pharmacodynamics and Pharmacokinetics of Empagliflozin and Torasemide in Patients With Type 2 Diabetes (NCT01276288) | Boehringer Ingelheim | 2011-01-01 |